Navamedic expands product footprint

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced the launch of four branded generic pharmaceuticals. The new products are initially introduced in the Dutch and Belgian markets.

 Furthermore, Navamedic has launched a series of eight branded oncology drugs in the Benelux markets. These products have until now been distributed by Navamedic in the Nordic markets only.

 "Navamedic will continue the expansion of our product portfolio in the months ahead and we expect 2013 to be an exciting year for the Company," said CEO Olof Milveden.

 The four generic drugs now being launched are:

  • Eltroxin® - treatment of patients with various thyroid deficiencies.
  • Lanoxin®  - treatment of various heart conditions, namely atrial fibrillation, atrial flutter and sometimes heart failure that cannot be controlled by other medication.
  • Imuran® - an immunosuppressive drug used in organ transplants and autoimmune diseases.
  • Zyloric®  - treatment of excess uric acid in the blood and complications caused by this, including chronic gout. 

 Navamedic has developed its product portfolio since the Company's first generics launch in 2011. Navamedic has a strong pipeline of candidates currently under review and is preparing to launch several new products in 2013. The Company expects to become a significant provider of generic drugs in the Nordic and Benelux markets over the next few years.

For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company. Through its subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of consumer, nutrition and pharmaceutical products in the Nordic markets. Navamedic is currently building up a generic pharmaceutical business for the Nordic, Dutch and Belgian markets based on its partnership with Aspen Healthcare of South Africa. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).


This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)